Yeztugo, a twice-yearly shot, could be the catalyst for stopping a recent spike in new HIV diagnoses. It's now available in ...

Milestone Pharmaceuticals Inc. is a strong buy after a 37% drop post-Cardamyst FDA approval. Click for this updated look at ...

Mark Cuban’s healthcare strategy targets high drug costs, insurance complexity and transparency, offering a simpler model ...

The recent federal reforms to pharmacy benefit managers are a meaningful step in the right direction, but the work is not ...

Milestone Pharma (MIST) stays a Hold after Q1 misses and a tough CARDAMYST launch; PSVT pricing, uptake, and payer risk loom.

Health care organizations need "financial flexibility," according to Joe Kight. Here's how he recommends achieving it.

Send a note to Maisha Shahid, Taylor Medine and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...